Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Bioneer Corporation (064550.KQ)
Daejeon, KR
Bioneer Corporation, established in 1992 and headquartered in Daejeon, South Korea, is a biotechnology company involved in diverse fields such as research products, molecular diagnostics, pharmaceuticals, and probiotics. For the biotechnology research market, Bioneer offers a wide array of consumables and reagents, including PCR and RT-PCR kits, real-time PCR solutions, RNA interference products, various chemicals, plastic laboratory essentials, and buffer solutions. The company also provides an extensive range of services like sample preparation, protein synthesis and purification, gene cloning, fluorescence dye and quencher services, electrophoresis, genome-wide functional analysis, and magnetic separation techniques. Additionally, Bioneer manufactures sophisticated instruments for conventional and real-time PCR, sample preparation, protein synthesis, centrifugation, vortex mixing, electrophoresis, spectrophotometry, and microbial culture. In molecular diagnostics, it supplies MDx technologies, human diagnostic kits, MDx extraction kits, and the necessary instrumentation. Furthermore, Bioneer develops specialized products for animal health and cutting-edge nano-biotechnology applications.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.06% | -5.36% | -8.72% | -27.14% | -33.31% | -24.90% | -44.14% | -78.63% | -44.59% | -29.41% | -31.44% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+12.3% ★ Q1'26: +10.8% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+86.3% ★ Q1'26: -3,134.4% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-3.0% Q1'26: -11.9% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+2.4% ★ Q1'26: -0.9% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+2.0% ★ Q1'26: -1.3% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.0% ★ Q1'26: +1.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×6.29× Q1'26: -35.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
23.27B
est: 25.00B (-6.9%)
|
24.08B
est: 36.00B (-33.1%)
|
36.29B
est: 25.00B (+45.2%)
|
206.99B
est: 36.00B (+475.0%)
|
223.74B
est: 34.20B (+554.2%)
|
218.39B
est: 221.60B (-1.4%)
|
263.24B
est: 278.80B (-5.6%)
|
293.98B
est: 321.90B (-8.7%)
|
330.11B
est: 443.20B (-25.5%)
|
516.20B
516.20B – 516.20B
+16.5% YoY
|
| EBITDA |
-4.79B
est: 3.24B (-248.0%)
|
-5.73B
est: 4.66B (-222.8%)
|
-1.11B
est: 3.24B (-134.3%)
|
62.17B
est: 4.66B (+1,233.0%)
|
48.79B
est: 4.43B (+1,001.1%)
|
21.78B
est: 28.71B (-24.1%)
|
10.29B
est: 36.12B (-71.5%)
|
-2.78B
est: 25.67B (-110.8%)
|
16.92B
est: 35.34B (-52.1%)
|
41.16B
41.16B – 41.16B
+16.5% YoY
|
| EBIT |
-8.70B
est: 2.52B (-444.8%)
|
-9.27B
est: 3.63B (-355.3%)
|
-5.44B
est: 2.52B (-315.6%)
|
57.48B
est: 3.63B (+1,482.8%)
|
43.77B
est: 3.45B (+1,168.5%)
|
14.52B
est: 22.36B (-35.0%)
|
1.34B
est: 28.13B (-95.2%)
|
-11.91B
est: 16.15B (-173.8%)
|
7.95B
est: 22.23B (-64.2%)
|
25.89B
25.89B – 25.89B
+16.5% YoY
|
| Net Income |
-9.94B
est: -5.96B (-66.7%)
|
-8.82B
est: -988.52M (-792.1%)
|
-7.83B
est: -5.96B (-31.3%)
|
57.90B
est: -988.52M (+5,957.1%)
|
27.16B
est: 490.39M (+5,438.4%)
|
12.08B
|
-10.59B
|
-20.58B
est: 5.86B (-451.3%)
|
-2.81B
est: 52.55B (-105.4%)
|
69.35B
69.35B – 69.35B
+32.0% YoY
|
| SGA |
3.62B
est: 11.80B (-69.3%)
|
3.30B
est: 17.00B (-80.6%)
|
5.16B
est: 11.80B (-56.3%)
|
40.33B
est: 17.00B (+137.3%)
|
83.17B
est: 16.15B (+415.1%)
|
134.22B
est: 104.62B (+28.3%)
|
151.48B
est: 131.63B (+15.1%)
|
177.57B
est: 177.76B (-0.1%)
|
196.53B
est: 244.75B (-19.7%)
|
285.06B
285.06B – 285.06B
+16.5% YoY
|
| EPS |
-539.41
est: -231.00 (-133.5%)
|
-427.57
est: -38.30 (-1,016.4%)
|
-360.86
est: -231.00 (-56.2%)
|
2,508.88
est: -38.30 (+6,650.6%)
|
1,073.38
est: 19.00 (+5,549.4%)
|
467.91
|
-410.19
|
-797.92
est: 227.00 (-451.5%)
|
-108.99
est: 2,036.00 (-105.4%)
|
2,687.00
2,687.00 – 2,687.00
+32.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-24 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-23 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Samsung Kodex Fn Growth ETF 325010.KS | 0.01% | 6.0K | 0.30% |
| 2 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 526.7K | 0.06% |
| 3 | Vanguard FTSE Developed Asia Pacific All Cap Index ETF VA.TO | 0.00% | 2.7K | 0.22% |
| 4 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 22.7K | 0.46% |
| 5 | Vanguard FTSE Pacific ETF VPL | 0.00% | 152.9K | 0.07% |
| 6 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 75.5K | 0.29% |
| 7 | Vanguard FTSE Developed All Cap ex North America Index ETF VIU.TO | 0.00% | 30.7K | 0.23% |
| 8 | Vanguard FTSE Developed All Cap ex North America Index ETF (CAD-hedged) VI.TO | 0.00% | 2.7K | 0.22% |
| 9 | Vanguard FTSE Developed All Cap ex U.S. Index ETF VDU.TO | 0.00% | 2.2K | 0.22% |
| 10 | Vanguard FTSE Developed All Cap ex U.S. Index ETF (CAD-hedged) VEF.TO | 0.00% | 3.5K | 0.22% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Geun-Bok Seo | Executive Officer | — | — |
| Han-Oh Park | Founder, Chief Executive Officer & Chairman | — | — |
| Jae-Ha Kim | Director and Director of Nano Bio Bus. Division | — | male |
| Jae-Hyung Yu | Head of Sales Division and Director | — | — |
| Jin-Pyeong Jeong | Director and Head of Management Support Division | — | — |
| Pil-Ho Lee | Executive Officer | — | — |
| Sang-Chul Kim | Executive Officer | — | male |
| Seung-Wook Ham | Executive Officer | — | — |
| Tai-Hyung Park | Executive Officer | — | male |
| Young-Cheol Choi | Executive Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 064550.KQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
